The COVID-19 pandemic brought mRNA vaccines to market in a short period, pointing the entire drug development field in the direction of mRNA treatment.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
All data in this study are available from the corresponding author upon request. Source data are provided with this paper.
Wolff, J. A. et al. Science 247, 1465–1468 (1990).
Weng, Y. et al. Biotechnol. Adv. 40, 107534 (2020).
Gaviria, M. & Kilic, B. Nat. Biotechnol. 39, 546–548 (2021).
Huang, X. et al. Nat. Med. 28, 2273–2287 (2022).
Jürgens, B. & Clarke, N. S. Nat. Biotechnol. 37, 370–375 (2019).
World Health Organization. International Classification of Diseases, 11th Revision (2022).
Shores, D. The mRNA patent and competitive landscape: pioneers, litigation outlook and big pharma’s next moves (Part III) (2021); https://www.ipwatchdog.com/2021/04/30/mrna-patent-competitive-landscape-pioneers-litigation-outlook-big-pharmas-next-moves-part-iii/id=132936/
Sanofi. Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics (2021); https://ml-eu.globenewswire.com/Resource/Download/076b7e7c-1a1e-4b6e-a620-129fb086f3a2
Sanofi. Safety and immunogenicity of quadrivalent influenza mRNA vaccine mrt5410 in adult participants 18 years of age and older (accessed 20 January 2023); https://clinicaltrials.gov/study/NCT05624606
21jingji. There are more than 10 mRNA vaccine companies in China. Who will be the first to be approved for listing? [in Chinese] (2022); http://www.21jingji.com/article/20220530/herald/0bf031e84c4b80d4699749e40721b16f.html
AIM Vaccine. AIM Vaccine completed acquisition of Lifanda to accelerate deployment of mRNA COVID-19 vaccine (2021); https://en.aimbio.com/content/details_17_447.html
Rikap, C. Rev. Int. Polit. Econ. 26, 987–1021 (2019).
Hou, X., Zaks, T., Langer, R. & Dong, Y. Nat. Rev. Mater. 6, 1078–1094 (2021).
Hajj, K. A. & Whitehead, K. A. Nat. Rev. Mater. 2, 17056 (2017).
Xiong, Q., Lee, G. Y., Ding, J., Li, W. & Shi, J. Nano Res. 11, 5281–5309 (2018).
Guan, S. & Rosenecker, J. Gene Ther. 24, 133–143 (2017).
Qin, S. et al. Signal Transduct. Target. Ther. 7, 166 (2022).
Baden, L. R. et al. N. Engl. J. Med. 384, 403–416 (2021).
Anderson, E. J. et al. N. Engl. J. Med. 383, 2427–2438 (2020).
Polack, F. P. et al. N. Engl. J. Med. 383, 2603–2615 (2020).
Lyu, L., Feng, Y., Chen, X. & Hu, Y. Nat. Biotechnol. 38, 1387–1394 (2020).
Schoenmaker, L. et al. Int. J. Pharm. 601, 120586 (2021).
Kim, S. C. et al. Mol. Cell. Toxicol. 18, 1–8 (2022).
Anonymous. Nat. Biotechnol. 40, 1160 (2022).
Reuters. BioNTech, Pfizer sue CureVac over COVID-19 vaccine patent claims (2022); https://www.businesstoday.in/industry/pharma/story/biontech-pfizer-sue-curevac-over-covid-19-vaccine-patent-claims-342815-2022-07-27
This work was supported by the National Natural Science Foundation of China (grants no. 81972392, 82102902, 82272769).
The authors declare no competing interests.
Peer review information
Nature Biotechnology thanks Mario Gaviria for his contribution to the peer review of this work.
About this article
Cite this article
Lyu, M., Chen, J., Peng, Y. et al. The global patent landscape of mRNA for diagnosis and therapy. Nat Biotechnol 41, 1193–1199 (2023). https://doi.org/10.1038/s41587-023-01925-2